[Rhabdomyolysis and unexplained malaise. Role of combination of ciprofibrate and norfloxacin].
Blain
H
H
Klein
M
M
Weryha
G
G
Tréchot
P
P
Hanesse
B
B
Leclère
J
J
D000890:Anti-Infective Agents / Q000009:adverse effects*; D002995:Clofibric Acid / Q000009:adverse effects / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D005260:Female; D058607:Fibric Acids; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D008875:Middle Aged; D009643:Norfloxacin / Q000009:adverse effects*; D012206:Rhabdomyolysis / Q000139:chemically induced*; D013575:Syncope / Q000139:chemically induced*
D000890:Anti-Infective Agents; D058607:Fibric Acids; D000960:Hypolipidemic Agents; D002995:Clofibric Acid; C019304:ciprofibrate; D009643:Norfloxacin
Rhabdomyolyse et malaises inexpliqués. Rôle de l'association ciprofibrate et norfloxacine.